Boehringer Ingelheim Animal Health do Brasil Ltda., a subsidiary of the global pharmaceutical giant Boehringer Ingelheim, is headquartered in Brazil and operates extensively across the Latin American region. Founded in 1885, the company has established itself as a leader in the animal health industry, focusing on innovative solutions for livestock and companion animals. With a diverse portfolio that includes vaccines, antiparasitics, and pharmaceuticals, Boehringer Ingelheim is renowned for its commitment to research and development, ensuring high-quality products tailored to the needs of veterinarians and animal owners. The company’s unique approach to animal health, emphasising sustainability and animal welfare, has solidified its market position as a trusted partner in the veterinary community. Notable achievements include significant advancements in disease prevention and treatment, contributing to the overall health and productivity of animals in Brazil and beyond.
How does Boehringer Ingelheim Animal Health do Brasil Ltda.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Animal Health do Brasil Ltda.'s score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Animal Health do Brasil Ltda. currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Boehringer Ingelheim GmbH, which may influence its climate commitments and performance metrics. As a part of its corporate family, Boehringer Ingelheim Animal Health do Brasil Ltda. inherits sustainability initiatives and targets from its parent company, Boehringer Ingelheim GmbH, at a cascade level of 2. However, there are no documented reduction targets or climate pledges specific to the Brazilian subsidiary. In the broader context, Boehringer Ingelheim GmbH has established various climate commitments, which may include science-based targets and sustainability initiatives aimed at reducing carbon emissions across its operations. These initiatives are crucial for aligning with global climate goals and enhancing environmental responsibility within the animal health sector. While specific emissions data and reduction targets for Boehringer Ingelheim Animal Health do Brasil Ltda. are not available, the company's affiliation with Boehringer Ingelheim GmbH suggests a commitment to sustainability and climate action in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim Animal Health do Brasil Ltda. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.